New York, New York, United States The overall number of key employees were 4.
The typical case for the fund is to invest in rounds with 6-7 participants. Despite the Laurion Capital Management, startups are often financed by Bill & Melinda Gates Foundation, WuXi AppTec, Scott Becker. The meaningful sponsors for the fund in investment in the same round are Samsara BioCapital, Pfizer Venture Investments, Perceptive Advisors.
The top activity for fund was in 2019. The common things for fund are deals in the range of 50 - 100 millions dollars. The fund is constantly included in 2-6 deals per year.
Among the most popular fund investment industries, there are Enterprise Software, Biotechnology. Besides, a startup requires to be at the age of more than 20 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Schrodinger.
Related Funds
| Fund Name | Location |
| Broadview Ventures | Boston, Massachusetts, United States |
| Caltech | California, Pasadena, United States |
| Elysian Park Ventures | California, Los Angeles, United States |
| Hollinger Digital Inc. | New York, New York, United States |
| Juniper Networks | California, Sunnyvale, United States |
| New Media Ventures | California, San Francisco, United States |
| Regional Cancer Care Associates | Hackensack, New Jersey, United States |
| Sanwa Butsuryu Service | Hokkaido Prefecture, Japan, Sapporo |
| Valley Growth Ventures | Ohio, United States, Youngstown |
| WME Ventures | New York, New York, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Aardvark Therapeutics | $85M | 09 May 2024 | San Diego, California, United States | ||
MerQube | $22M | 13 Jul 2023 | San Francisco, California, United States | ||
Opensee | $12M | 15 Dec 2022 | Paris, Ile-de-France, France | ||
TRex Bio | $26M | 08 Mar 2022 | South San Francisco, California, United States | ||
Ambys Medicines | $47M | 21 Dec 2021 | - | ||
AnHeart Therapeutics | $61M | 14 Dec 2021 | Shangcheng District, Zhejiang, China | ||
Racket.com | $3M | 16 Nov 2021 | Los Angeles, California, United States | ||
LEXEO Therapeutics | $100M | 09 Sep 2021 | New York, New York, United States | ||
Pyxis Oncology | $152M | 30 Mar 2021 | Boston, Massachusetts, United States |
– Exscientia is an Oxford, England, UK-based clinical stage pharmatech company using AI to design patient-based drugs.
– SoftBank Vision Fund 2 led the Series D funding round and was joined by previous round lead investors – Novo Holdings and funds managed by Blackrock.
– Other investors included Mubadala Investment Company, Farallon Capital, Casdin Capital, GT Healthcare Capital, Marshall Wace, Pivotal bioVenture Partners, Laurion Capital, Hongkou and Bristol-Myers Squibb.
– In addition to the Series D funding round, SoftBank is providing an additional $300m equity commitment that can be drawn at the company’s discretion.
– Pyxis Oncology from Longwood Fund has closed a $152m Series B financing.
– The round was led by Arix Bioscience and co-led by RTW Investments, LP.
– New investors included Perceptive Advisors, RA Capital Management, Pfizer Ventures, BVF Partners, L.P., Janus Henderson Investors, Cormorant Asset Management, HBM Healthcare Investments, funds managed by Tekla Capital Management LLC, Acuta Capital Partners, Ridgeback Capital Investments, Surveyor Capital (a Citadel company), Laurion Capital Management, Logos Capital and LifeSci Venture Partners.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Aardvark Therapeutics | $85M | 09 May 2024 | San Diego, California, United States | ||
MerQube | $22M | 13 Jul 2023 | San Francisco, California, United States | ||
Opensee | $12M | 15 Dec 2022 | Paris, Ile-de-France, France | ||
TRex Bio | $26M | 08 Mar 2022 | South San Francisco, California, United States | ||
Ambys Medicines | $47M | 21 Dec 2021 | - | ||
AnHeart Therapeutics | $61M | 14 Dec 2021 | Shangcheng District, Zhejiang, China | ||
Racket.com | $3M | 16 Nov 2021 | Los Angeles, California, United States | ||
LEXEO Therapeutics | $100M | 09 Sep 2021 | New York, New York, United States | ||
Pyxis Oncology | $152M | 30 Mar 2021 | Boston, Massachusetts, United States |
